Please enable JavaScript.

Coggle requires JavaScript to display documents.

Patient (Atorvastatin (Lipitor) (Indication (Hypertension, Dyslipidemia,…

- - - - Initial changes 3-5 days
      - Maximal reduction in 2-4 weeks
    - - Hepatic via CYP3A4
    - - 14 hours
    - - Bile
      - Urine
    - - Individualized according to baseline LDL-cholesterol concentrations and patient response
        
        adjustments made every 2 - 4 weeks
  - - - Compensatory increase inxpression of LDL receptors on hepatocyte membranes
- - - - Acyclovir
      - Valacyclovir
  - - - 7-10 days (longer if needed)
    - - To acyclovir aldehyde by alcohol dehydrogenase
        
        converted to CMMG 9-[(carboxymethoxy)methyl]guanine
    - - 2.5 hours
    - - Urine
    - - 400 mg tid
      - 200 mg 5x / day
  - - - Acyclovir diphosphate
        
        Converted to acyclovir triphosphate (active form) by cellular elements
- - - - 2 - 5 days
    - - Hepatic via CYP2C9
    - - Urine
    - - 20-60 hours (highly variable)
    - - Individualized
      - Start 2 - 5 mg once daily for healthy individuals
  - - - II
      - VII
      - IX
      - X
- - - - 2 - 4 hours
    - - Hepatic via CYP3A and 2D6
    - - 3 - 5 hours
    - - Urine
      - Feces
    - - 600 mg twice daily
- - - - 3 hours emtricitabine
      - 1 hour tenofovir alafenamide
    - - emtricitabine not significantly metabolized
      - tenofovir alafenamide intracellular metabolism, minimal extent by CYP3A
    - - 10 hours emtricitabine
      - 0.51 hours tenofovir alafenamide
    - - Urine
      - Feces
    - - One tablet daily (200 mg emtricitabine / 25 mg tenofovir alafenamide)
- - - - 2.5 - 4 hours
    - - Hepatic via CYP3A
    - - 15 hours
    - - Feces
      - Urine
    - - 800 mg once daily